Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Has not recovered to common terminology criteria for adverse events (CTCAE) Grade 1 or better from any adverse events that were due to cancer therapeutics administered more than 4 weeks earlier. Participants receiving ongoing replacement hormone therapy for endocrine immune-related AEs will not be excluded from participation in this study

Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years

History of hyperparathyroidism or hypercalcemia

Has one or more of the following ophthalmological findings/conditions: a) Intraocular pressure >21 mm Hg and/or any diagnosis of glaucoma b) Diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion and c) Diagnosis of retinal degenerative disease